Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
PRINCETON - On Thursday, Integra LifeSciences Holdings Corporation (NASDAQ:IART) reported third-quarter earnings that exceeded analyst expectations, despite falling short on revenue targets.
The company’s shares fell 2.79% in pre-market trading following the mixed results and lowered guidance.
The medical technology company posted adjusted earnings of $0.54 per share for the third quarter, surpassing the analyst consensus of $0.43. However, revenue came in at $402.1 million, missing the expected $414.23 million. Compared to the same period last year, revenue increased 5.6% on a reported basis and 5.0% on an organic basis.
"In the third quarter, we continued to see healthy demand across our portfolio. While revenue was impacted by two supply interruptions, we delivered strong profitability and cash flow through disciplined cost management and operational efficiencies," said Mojdeh Poul, president and chief executive officer.
The company’s Codman Specialty Surgical segment, which represents about 70% of total revenue, grew 8.1% on a reported basis to $292.6 million. Meanwhile, the Tissue Technologies segment saw a slight decline of 0.5% to $109.5 million.
Integra lowered its fourth-quarter guidance, now expecting revenue between $420 million and $440 million, below the consensus estimate of $456.2 million. The company also reduced its full-year 2025 revenue outlook to $1.62-1.64 billion, down from the analyst consensus of $1.67 billion.
For the fourth quarter, Integra forecasts adjusted earnings of $0.79-$0.84 per share, below the $0.92 consensus. The full-year EPS guidance of $2.19-$2.24 is in line with analyst expectations of $2.21.
"We are making progress in implementing our comprehensive plan to systematically strengthen the entirety of our supply chain and quality management system, and we remain confident in our strategy to improve overall performance and drive the Company’s transformation," Poul added.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.